|
Sam Brown Inc. is proud to work with a
number of impressive pharmaceutical, biotechnology and
healthcare companies. We notably recognize our founding
clients DuPont, GlaxoSmithKline, Yamanouchi Pharmaceuticals
and the Rohm and Haas Company.
AltheRx
Pharmaceuticals
Formed in 2010, AltheRx Pharmaceuticals is a privately
held development company whose business model is to advance
projects through clinical development and create
partnerships with biopharmaceutical companies for
commercialization. The Company’s first product, Solabegron,
is a highly selective and potent beta3-adrenoceptor agonist
in development for the reduction of symptoms of Overactive
Bladder and Irritable Bowel Syndrome.
www.altherx.com
Astellas
Pharma Inc.
Astellas Pharma Inc. is a pharmaceutical company
dedicated to improving the health of people around the world
through provision of innovative and reliable
pharmaceuticals. The organization is committed to becoming a
global category leader in Oncology, and has several oncology
compounds in development in addition to MDV3100.
www.astellas.com/en
Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Princeton,
NJ, and Vancouver, BC, is a privately held pharmaceutical
company developing new and more effective therapies to treat
cancer. CombiPlex®, the company's proprietary drug ratio
technology platform, represents a novel approach that
identifies molar ratios of drugs that will deliver a
synergistic benefit, and locks the desired ratio in a nano-scale
drug delivery vehicle that maintains the ratio in patients
with the goal of improving clinical outcomes.
www.celatorpharma.com
Enteromedics Inc.
EnteroMedics is a development stage medical device
company focused on the design and development of devices
that use neuroblocking technology to treat obesity,
metabolic diseases, and other gastrointestinal disorders.
EnteroMedics' proprietary neuroblocking technology, VBLOC®
vagal blocking therapy, is designed to intermittently block
the vagus nerves using high-frequency, low-energy,
electrical impulses. These electrical impulses are delivered
by a neuroregulator, EnteroMedics' Maestro® System, which is
powered by an integrated rechargeable battery.
www.enteromedics.com
Formula
Pharmaceuticals, Inc.
Formula Pharmaceuticals, Inc. is a privately-held,
oncology drug development company advancing novel medicines
to address areas of unmet therapeutic need in cancer.
Formula’s lead product candidate, FPI-01, is a
first-in-class immunotherapeutic in clinical development for
the maintenance of first-remission in acute myeloid leukemia
(AML) and other cancers. Building upon deep industry
expertise in identifying, licensing and developing novel
medical approaches, Formula's focus is on accelerating
future life-saving cancer therapies.
www.formulapharma.com
Galleon
Pharmaceuticals
Galleon is the first pharmaceutical company to focus
primarily on the drug treatment of breathing-control
disorders. Its initial goals are to improve the safety,
efficacy and economics associated with the acute care of
surgical patients and longer-term care of patients with
conditions such as moderate-to-severe pain or sleep apnea.
The company’s product pipeline reflects recent advances in
neurobiology, molecular biology and respiratory medicine
which have enabled the development of a unique
drug-discovery platform and promising drug candidates that
are now undergoing clinical trials. Galleon’s integrated
discovery and development approach is unique among
pharmaceutical companies and enables the rapid evaluation of
multiple variables to establish a comprehensive profile of
breathing-control activity.
www.galleonpharma.com
GlaxoSmithKline
GlaxoSmithKline – one of the world’s leading research-based
pharmaceutical and healthcare companies – is committed to
improving the quality of human life by enabling people to do
more, feel better and live longer.
www.gsk.com
H3 Biomedicine Inc.
H3 Biomedicine Inc. is a privately held, uniquely
structured drug discovery enterprise that is integrating
insights from cancer genomics with innovative capabilities
in synthetic chemistry and tumor biology to generate novel
small-molecule drugs to treat cancer. With a $200-million
research funding commitment from the global human health
care company, Eisai, and access to its worldwide development
capabilities, H3 Biomedicine is well positioned to address
some of the most challenging cancers by delivering on its
scientific vision of patient-based, genomics-driven drug
discovery.
www.H3biomedicine.com
About HealthCoach4Me
HealthCoach4Me.com is a novel, virtual health-coaching web
site for people who want to take charge of their health.
HealthCoach4Me.com builds interactive and customizable
coaching plans based on goals of the patient. GSK is
currently rolling out the site to managed care companies,
patient advocacy groups and medical and healthcare
associations. Consumers can also directly access the site.
www.HealthCoach4Me.com
Health Resource
Alliance
Health Resource Alliance (HRA) develops innovative products,
programs, and services designed to optimize the
effectiveness of organizations serving seniors. HRA address
the spectrum of senior healthcare needs: prescription drug
management, , rehabilitation therapies, wellness activities,
and programs to ensure seniors are living in environments
that best suit their needs.
www.hranet.org
Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on
discovering and developing proprietary, orally available
drugs for serous unmet medical needs in oncology and
inflammation. Incyte has a portfolio of novel compounds that
have advanced into late-stage clinical development.
www.incyte.com
MEDA
MEDA is an international specialty pharma company that
concentrates on marketing and market-adapted product
development. Acquisitions and long-term partnerships are
fundamental factors that drive the company’s strategy.
Meda's prioritised therapy areas are respiratory,
cardiology, pain and inflammation, and dermatology –
including drugs such as Astelin® (azelastine), a nasal spray
for treatment of allergic and non-allergic rhinitis, and
SOMA® (carisoprodol, a muscle relaxant used to treat acute
pain.
www.medapharma.us
Medivation, Inc.
Medivation, Inc. is a biopharmaceutical company focused
on the rapid development of novel small molecule drugs to
treat serious diseases for which there are limited treatment
options. Medivation aims to transform the treatment of these
diseases and offer hope to critically ill patients and their
caregivers. Together with its corporate partners Astellas
and Pfizer, Medivation currently has investigational drugs
in Phase 3 development to treat advanced prostate cancer and
mild-to-moderate Alzheimer's disease.
www.medivation.com
Tetraphase
Pharmaceuticals
Tetraphase Pharmaceuticals is a clinical stage
biopharmaceutical company utilizing its breakthrough
synthetic chemistry technology platform to discover and
develop next-generation tetracycline antibiotics that
address unmet needs such as the treatment of serious drug
resistant and gram-negative infections. The company has
developed an emerging pipeline of potent novel antibiotics
that provide a portfolio of intravenous and oral drug
candidates with the potential to treat a wide range of
infections, including broad-spectrum and selective-spectrum
infections.
www.tphase.com
Together Rx Access
The Together Rx Access Card was created by many of the
nation’s leading pharmaceutical companies to help
hardworking Americans and their families gain access to
immediate and meaningful savings on prescription products
right at their neighborhood pharmacy. Medicines in the
Program include those used to treat high cholesterol,
diabetes, depression, asthma, and many other common
conditions. The Together Rx Access Card is free to get and
free to use.
www.togetherrxaccess.com
Xenoport, Inc.
XenoPort, Inc. is a biopharmaceutical company focused on
developing a portfolio of internally discovered product
candidates that utilize the body's natural nutrient
transport mechanisms to improve the therapeutic benefits of
existing drugs. XenoPort is developing its lead product
candidate in partnership with Astellas Pharma Inc. and
GlaxoSmithKline.
www.xenoport.com
Yaupon
Therapeutics
Yaupon Therapeutics is a privately held, specialty
pharmaceutical company that develops small molecule
pharmaceuticals licensed from under-served academic
institutions. The Company’s lead product candidate is a
proprietary topical mechlorethamine gel that recently
completed a pivotal trial under a Special Protocol
Assessment (SPA) with the Food and Drug Administration (FDA)
for the treatment of early-stage cutaneous T-cell lymphoma.
In addition, Yaupon has a pipeline of earlier-stage
products.
www.yaupontherapeutics.com
|
